Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition

NCT ID: NCT02185833

Last Updated: 2014-07-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2014-06-30

Brief Summary

To assess the bioequivalence of the investigational TEST product with the marketed REFERENCE products by measurement of Plasma concentrations of Erythromycylamine and calculation of the bioequivalence parameters from those measurements followed by ANOVA and 90% confidence interval statistical evaluation.

Detailed Description

An open-label, randomized, two-treatments, two-periods, two-sequences, crossover bioequivalence pilot study with a washout period of at least 14 days between doses. Healthy, mixed skin Arab & Mediterranean Subjects ages between 18 and 50 years, body-mass index 18.5 to 30.0 kg/m2 inclusive (minimum of 50 kg weight), non-smokers or light smokers (smokers of not more than 10 cigarettes per day).

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

DIRITHROMYCIN 500 MG ENTERIC COATED TABLET

DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once

Group Type: EXPERIMENTAL

DIRITHROMYCIN 500 MG ENTERIC COATED TABLET

Intervention Type: DRUG

DYNABAC 250 MG ENTERIC COATED TABLET

DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once

Group Type: ACTIVE_COMPARATOR

DYNABAC 250 MG ENTERIC COATED TABLET

Intervention Type: DRUG

Interventions

DIRITHROMYCIN 500 MG ENTERIC COATED TABLET

Intervention Type: DRUG

DYNABAC 250 MG ENTERIC COATED TABLET

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy subjects.

2. Ethnic Group: Arab & Mediterranean.

3. Race: Mixed skin (white & black skin people).

4. Age 18-50 years.

5. Body-mass index 18.5 to 30.0 kg/m2 inclusive. (minimum of 50 kg weight)

6. Subject is available for the whole study period and gave written informed consent.

7. Normal Physical examination.

8. Vital signs within normal ranges.

9. All laboratory screening results within the normal range, or being assessed as clinically Non-significant by the attending physician.

10. Normal Kidney & Liver functions test

Exclusion Criteria

1. Women of childbearing potential who don't use any contraceptive method, pregnant and/or lactating women.

2. Ethnic Group (Non- Arab &/ or Non- Mediterranean)

3. History of severe allergy or allergic reactions to study drug or related drugs or heparin

4. Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs

5. History of serious illness that can impact fate of drugs

6. Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, hematological, liver or kidney disease.

7. Clinically significant illness 4 weeks before study Period I

8. Mental disease.

9. Smoking of more than 10 cigarettes per day

10. Intake of Alcohol, caffeine, or xanthine beverages 16 hrs before each study drug administration.

11. Regular use of medication.

12. Having taken medication that could affect the investigated drug product: a) Regular consumption of drugs during the two weeks prior to study initiation day, b) consumption of enzyme stimulating or inhibiting drugs (e.g. Barbiturates, Carbamazepine, Phenytoin, Amphetamine, Benzodiazepine, cannabinoid, cocaine, opiates, phencyclidine and methadone) during one month before the study initiation.

13. Presence of any significant physical or organ abnormality

14. Donation of 1) at least 400 ml of blood within 60 days, or 2) more than 150 ml of blood within 30 days, or 3) more than 100 ml blood plasma or platelets within 14 days before study Period I

15. Participation in another bioequivalence study and/or Clinical trials within 80 days prior to the start of this study Period I

16. Following a special diet (e.g. vegetarian) or dieting one month before the study initiation.

17. Prior history of hypersensitivity to dirithromycin, erythromycin, or other macrolide antibiotics

18. Subjects with seizures or prior history of seizures

19. Any significant clinical abnormality including HBsAg, HCV, and / or HIV.

20. Consumption of grapefruit or grapefruit containing products within 7 days of drug administration

21. Ingestion of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.

22. Exhausting physical exercise in the last 48 hours (e.g. weight lifting) or any recent significant change in dietary or exercise habits.

23. Abnormal Vital Signs.

24. Abnormal Kidney and/or Liver functions test.

25. Vomiting, Diarrhea on admission

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Abdi Ibrahim Ilac San. ve Tic A.S.

INDUSTRY

Sponsor Role: collaborator

Pharmaceutical Research Unit, Jordan

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rana T Bustami, Phd.pharmacy

Role: PRINCIPAL_INVESTIGATOR

PRU

Locations

Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit

Amman, , Jordan

Countries

Jordan

Other Identifiers

DIRI502/PRO-00

Identifier Type: -

Identifier Source: org_study_id